131I治疗分化型甲状腺癌肝转移

对5例分化型甲状腺癌(DTC)肝转移患者进行了131I治疗后随访.结果表明(1)经131I治疗后生存期2-9年,2001年底随访时均存活.(2)1例在131I治疗11次(44.77 GBq)后131I扫描和B超示肝转移灶消失.(3)甲状腺双侧全切者,131I清除术后剩余甲状腺平均次数3.0次,平均总清除剂量14.58 GBq;而单侧切除者,平均清除次数3.7次,平均总清除剂量20.24 GBq,明显高于前者(P＜0.05).(4)131I首次剂量低于3.7 GBq者,清除术后剩余甲状腺平均次数5.5次,平均总清除剂量28.27 GBq;而首次剂量3.7 GBq者,平均清除次数2.0次,平均总清除剂量11.0GBq,差异非常显著(P＜0.01).提示术后131I治疗有可能控制病情发展、局限转移灶、提高生活质量和延长生存期.

131I treatment of liver metastases of differentiated thyroid cancer

5 cases of liver metastases of differentiated thyroid cancer (DTC) were given follow-up after 131I therapy. The results were evaluated with clinical appearence, blood examination, radionuclide imaging and survival analysis. The results showed that (1) all cases had survived for 2-9 years in follow-up period; (2) liver metastastic lesion was disappeared after taking 44.77 GBq 131I, as demonstrated by 131I scan and ultrasonic imaging; (3) the sequences and doses of 131I for normal ablation were significantly decreased with total thyroidectomy than with partial-thyroidectomy(P<0.05); (4) the sequences and doses of 131I for normal ablation were significantly decreased with 3.7 GBq initial 131I doses than with <3.7GBq (PO.01). The treatment of 131I with liver metastases from DTC may improve clinical symptoms, raise life quality, reduce lesion size, and prolong life survival.